Glycopyrronium Bromide is superior to Trihexyphenidyl for Reducing Drooling in Children with Cerebral Palsy— An Unregistered Randomized Controlled Trial
Abstract
Background: Cerebral palsy is frequently associated with
drooling or anterior sialorrhoea. This study was aimed to
compare the efficacy of Glycopyrronium bromide and
Trihexyphenidyl to reduce drooling in children with cerebral
palsy (CP).
Materials and Methods: A single-centered, unregistered,
randomized controlled trial was conducted from January to
December 2022 on 100 children (aged 3–14 years) diagnosed
with CP. The patients receiving conservative therapy without
any medical or surgical intervention were included in the
study. The study subjects were divided into two groups: 50
received oral glycopyrronium bromide, and 50 received oral
trihexyphenidyl. Glycopyrronium bromide was administered
starting at 0.02 mg/kg three times daily, titrated up to 0.1 mg/
kg. Trihexyphenidyl was administered starting at 1 mg daily,
increasing to a maximum of 2 mg three times a day. Followups
were conducted at 1, 3, and 6 months to assess drooling
severity and frequency using the Thomas Stonell and
Greenberg drooling rating scale.